Chinese biopharma stocks surged on Monday following reports that the U.S. Treasury Department is considering new rules that would allow American pharmaceutical companies to continue licensing most drugs developed by Chinese firms. This potential policy shift has driven gains in key Chinese biopharma shares such as Innovent Biologics, which rose 7%, and Akeso, which jumped 8%. The Hang Seng Biotech Index also climbed by over 5%, reflecting optimistic investor sentiment in the sector.

The proposed regulatory approach would distinguish biopharmaceuticals from other high-tech fields like artificial intelligence and semiconductors, where the U.S. has imposed tighter restrictions on China. However, the new rules would likely exclude certain sensitive areas involving pathogens or biotechnology with weaponization potential. These measures remain under development and subject to change, according to reports citing sources familiar with the process.

In recent years, Chinese companies have become significant players in global drug licensing, accounting for nearly half of U.S. deals to license drugs from overseas in 2025. China's pharmaceutical export momentum continues to build, with a record 81 out-licensing agreements worth $110 billion completed in the first half of 2026. Pfizer exemplifies this trend, having partnered with Innovent Biologics on a $10.5 billion collaboration focused on oncology drug development.

Despite ongoing geopolitical tensions, investors appear largely unfazed by uncertainties in the sector, drawn by Chinese companies' robust capabilities in novel drug innovation. China’s government has emphasized globalization within its 15th five-year plan for pharmaceuticals and biotechnology, which supports expectations that cross-border licensing deals with the U.S. will maintain strong growth moving forward.